Clik here to view.
Clinical Innovations通过在中国成立全资子公司布局加速全球增长战略
盐湖城 (美国商业资讯) — Clinical Innovations是世界领先的专门致力于妊娠分娩及新生儿重症监护的医疗器械制造商之一，公司今天宣布在中国成立禧暧医疗器械（上海）有限公司/CI Medical Device（Shanghai） Co., Ltd。新成立的全资子公司总部位于上海，其成立标志着Clinical Innovations全球增长战略的战略性加速。 Clinical...
View ArticleClik here to view.
Genome Editing Biotech EdiGene Names Dong Wei, Ph.D., MBA as its Chief...
BEIJING & CAMBRIDGE, Mass. EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Taro to Announce First Quarter Results on August 9, 2018
HAWTHORNE, N.Y. Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2018, after the close of market on...
View ArticleClik here to view.
Glaukos Announces Pharmaceutical Development Agreement with D. Western...
SAN CLEMENTE, Calif. Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and...
View ArticleClik here to view.
グラミネックス、女性のPMSと更年期症状の処置に花粉エキスを使用するというセレリスの特許への異議申し立てに成功
米オハイオ州デシュラー （ビジネスワイヤ） — グラミネックスは、米国特許局がセレリスの特許を拒絶したとことを発表します。この特許は女性のPMSと更年期症状の処置に同社の花粉エキスを使用するというものです。 米国特許第6569471号および第6669967号を並行して再審査したところ、米国特許局は最近、両特許の請求項すべてを拒絶しました。提出された圧倒的な証拠に基づき、同局は溶剤抽出のGC...
View ArticleClik here to view.
Graminex® LLC成功挑战Serelys将花粉萃取物用于治疗女性经前症候群及更年期症状的专利
俄亥俄州德什勒 (美国商业资讯) — Graminex® LLC欣然宣布，美国专利局已驳回Serelys公司将其花粉萃取物用于治疗女性经前症候群及更年期症状的专利。 美国专利局最近在针对美国专利6,569,471和6,669,967的平行复查审理中，驳回了这两项专利的所有宣称。依据所提交的压倒性证据，专利局认为，对于所谓的溶剂萃取GC FEM和PI...
View ArticleClik here to view.
China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir,...
FOSTER CITY, Calif. Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine...
View ArticleClik here to view.
KIST: Overcoming the Current Limitations of Cancer Immunotherapy Through...
SEOUL, South Korea Cancer immunotherapy harnessing the immune system to treat cancer is drawing a lot of attention of many medical staff and researchers because of unprecedented responses in the...
View ArticleClik here to view.
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License...
SAN DIEGO & MELBOURNE, Australia ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American...
View ArticleClik here to view.
和铂医药与Glenmark Pharmaceuticals签署同类首创双特异性抗体药物战略合作与独家授权协议
中国上海，美国波士顿，印度孟买和瑞士La Chaux de Fonds (美国商业资讯)–全球化的生物制药公司和铂医药与Glenmark Pharmaceuticals S.A. 宣布签署一项独家授权协议，在大中华区开发、生产以及商业化GBR 1302。这是一种由Glenmark开发的用于治疗HER2阳性癌症的靶向HER2和CD3的双特异性抗体创新药物。...
View ArticleClik here to view.
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China...
BOSTON & SHANGHAI & MUMBAI, India & LA CHAUX DE FONDS, Switzerland Harbour BioMed and Glenmark Pharmaceuticals S.A., announced today that they have entered into an exclusive license...
View ArticleClik here to view.
Synergy Pharmaceuticals Announces License Agreement with Luoxin...
NEW YORK Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced today that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing...
View ArticleClik here to view.
Celltrion Enters into Phases 1 and 3 Clinical Trials for the Adalimumab...
INCHEON, South Korea Celltrion (KRX:068270) applied for the clinical trials for its adalimumab biosimilar ‘CT-P17’, as a rheumatoid arthritis therapeutic agent, to the MHRA (Medicines and Healthcare...
View ArticleClik here to view.
Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and...
View ArticleClik here to view.
Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class...
REDWOOD CITY, Calif. & OSAKA, Japan Ambys Medicines, a biotechnology company focused on the discovery and development of transformative therapies for people with serious liver disease, and...
View ArticleClik here to view.
Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B...
BEIJING & CAMBRIDGE, Mass. EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
2018年上期における米国FDA新薬承認申請の95%をCertara社のソフトウェアやサービスがサポート
ニュージャージー州プリンストン モデルを活かした医薬品開発、レギュラトリー・サイエンス、市場アクセスおよびリアルワールド・エビデンス・サービスの分野で世界をリードするCertara®社は、2018年上期の米国食品医薬品局 (FDA)...
View ArticleClik here to view.
Certara Software or Services Supported 95% of the US FDA Novel Drug Approvals...
PRINCETON, N.J. Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today reported that 95% of novel new drug...
View ArticleClik here to view.
AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number...
View ArticleClik here to view.
Modulus Raises 800M Japanese Yen for Its Series A Funding Round
TOKYO Modulus Discovery, Inc., an early stage drug discovery company announced today that it has successfully raised a total of 800M Japanese Yen (approximately US $7.2M) for its series A round, led...
View Article